Literature DB >> 3183054

Potentiation of pentazocine analgesia by low-dose naloxone.

J D Levine1, N C Gordon, Y O Taiwo, T J Coderre.   

Abstract

The analgesia produced by combinations of low-dose naloxone with pentazocine or morphine was studied in 105 patients with moderately severe postoperative pain after standardized surgery for removal of impacted third molars. Pain intensity was quantified using a visual-analogue scale. To eliminate the release of endogenous opioids produced by the placebo component of open drug administration, all injections were made by a preprogrammed infusion pump. The analgesia produced by pentazocine, an agonist-antagonist opiate-analgesic acting predominantly at the kappa opiate receptor, was potentiated by low-dose naloxone, whereas the analgesia produced by morphine, a mu-agonist, was attenuated by low-dose naloxone. To evaluate whether similar potentiation would be present in an animal model, and specifically, in the absence of diazepam, which patients receive, we performed an analogous experiment in rats in which nociceptive threshold was determined using the Randall-Selitto paw-withdrawal test. The results were completely analogous to the clinical results: pentazocine analgesia was potentiated by low-dose naloxone, whereas morphine analgesia was attenuated by low-dose naloxone. These data demonstrate a novel interaction between opiates, and suggest a rationale for opiate combinations to produce potent analgesia with fewer autonomic side effects and less abuse potential than presently available analgesics.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3183054      PMCID: PMC442725          DOI: 10.1172/JCI113768

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Antinociceptive activitiy of narcotic agonist and partial agonist analgesics and other agents in the tail-immersion test in mice and rats.

Authors:  R D Sewell; P S Spencer
Journal:  Neuropharmacology       Date:  1976-11       Impact factor: 5.250

2.  Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain.

Authors:  J D Levine; N C Gordon; H L Fields
Journal:  Nature       Date:  1979-04-19       Impact factor: 49.962

3.  Low dose naloxone enhances buprenorphine in a tooth pulp antinociceptive assay.

Authors:  S A Bergman; R L Wynn; D E Myers; F G Rudo
Journal:  Arch Int Pharmacodyn Ther       Date:  1988 Jan-Feb

4.  Differential effects of morphine on responses of dorsal horn lamina V type cells elicited by A and C fibre stimulation in the spinal cat.

Authors:  D Le Bars; G Guilbaud; I Jurna; J M Besson
Journal:  Brain Res       Date:  1976-10-22       Impact factor: 3.252

5.  The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog.

Authors:  P E Gilbert; W R Martin
Journal:  J Pharmacol Exp Ther       Date:  1976-07       Impact factor: 4.030

6.  Naloxone alters pain perception and somatosensory evoked potentials in normal subjects.

Authors:  M S Buchsbaum; G C Davis; W E Bunney
Journal:  Nature       Date:  1977-12-15       Impact factor: 49.962

7.  Enhancement of a nociceptive reaction by opioid antagonists in mice.

Authors:  J J Jacob; K Ramabadran
Journal:  Br J Pharmacol       Date:  1978-09       Impact factor: 8.739

8.  Increased analgesic activities of a fluorinated and a dimeric analogue of [D-Ala-2]-methionine enkephalinamide.

Authors:  D H Coy; A J Kastin; M J Walker; R F McGivern; C A Sandman
Journal:  Biochem Biophys Res Commun       Date:  1978-08-14       Impact factor: 3.575

9.  The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone).

Authors:  D R Jasinski; W R Martin; C A Haertzen
Journal:  J Pharmacol Exp Ther       Date:  1967-08       Impact factor: 4.030

10.  Hyperalgesia induced by naloxone follows diurnal rhythm in responsivity to painful stimuli.

Authors:  R C Frederickson; V Burgis; J D Edwards
Journal:  Science       Date:  1977-11-18       Impact factor: 47.728

View more
  9 in total

1.  Summary of the scientific literature for pain and anxiety control in dentistry.

Authors:  L C Hassett
Journal:  Anesth Prog       Date:  1989 May-Jun

2.  Involvement of mu-opioid receptors in the antitussive effects of pentazocine.

Authors:  J Kamei; K Katsuma; Y Kasuya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-02       Impact factor: 3.000

Review 3.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Opioid receptors and pain.

Authors:  R Dirksen
Journal:  Pharm Weekbl Sci       Date:  1990-04-27

5.  Agonist-antagonist combinations in opioid dependence: a translational approach.

Authors:  P Mannelli
Journal:  Dipend Patologiche       Date:  2010

6.  Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.

Authors:  S M Crain; K F Shen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

7.  A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain.

Authors:  Smita Kshirsagar; Robert Gear; Jon Levine; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.745

8.  Ligand directed signaling differences between rodent and human κ-opioid receptors.

Authors:  Selena S Schattauer; Mayumi Miyatake; Haripriya Shankar; Chad Zietz; Jamie R Levin; Lee-Yuan Liu-Chen; Vsevolod V Gurevich; Mark J Rieder; Charles Chavkin
Journal:  J Biol Chem       Date:  2012-10-19       Impact factor: 5.157

Review 9.  Tolerance and withdrawal from prolonged opioid use in critically ill children.

Authors:  Kanwaljeet J S Anand; Douglas F Willson; John Berger; Rick Harrison; Kathleen L Meert; Jerry Zimmerman; Joseph Carcillo; Christopher J L Newth; Parthak Prodhan; J Michael Dean; Carol Nicholson
Journal:  Pediatrics       Date:  2010-04-19       Impact factor: 7.124

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.